TRiCares’ Topaz transfemoral tricuspid heart valve replacement system is designed as a treatment for patients who require tricuspid valve repair but are not able to withstand open heart surgery. Image Credit: Prachova Nataliia / Shutterstock.

European device company TRiCares has raised $50m in a Series D financing round to develop its transfemoral tricuspid heart valve replacement system, Topaz.

The company plans to use the funds to conduct an early feasibility study in the US and initiate a pivotal trial in Europe. Additionally, the investment will  be used to develop more valve sizes for Topaz. The Series D funds were raised from a single, strategic unnamed investor.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

TRiCares has received an Investigational Device Exemption (IDE) from the US Food and Drug Administration (FDA) to conduct an early feasibility study, due to start later this year. The company plans to enrol patients across eight sites in the US and Canada and start a pivotal trial for obtaining a CE Mark for Topaz in Europe soon.

Valve replacement is done in patients with severe valvular heart disease. As blood flows around these valves it causes high stress, thereby, activating platelets and coagulation. TRiCares’ Topaz system is designed as a treatment for patients who require tricuspid valve repair but are not able to withstand open heart surgery or for whom the open surgery may be too risky.

GlobalData expects the transcatheter tricuspid valve replacement market to grow from being worth $10m in 2023 to over $2bn in 2033. The growth will be driven by the increased adoption of these devices and surgeons becoming more familiar with these procedures.

GlobalData is the parent company of Clinical Trials Arena.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Multiple companies are developing tricuspid valves. In April, Abbott’s TriClip transcatheter edge-to-edge repair (TEER) system was cleared by The US FDA to treat tricuspid regurgitation. In May, Meacor raised $15m in Series A financing to develop its Cryocinch system, a new minimally invasive treatment for mitral and tricuspid valve regurgitation.

Clinical Trials Arena Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving clinical trials industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now